{"id":"olmesartan-medoxomil-probenecid","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Renal impairment"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal upset (probenecid-related)"}]},"_chembl":{"chemblId":"CHEMBL1200692","moleculeType":"Small molecule","molecularWeight":"558.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that reduces vasoconstriction and aldosterone secretion, thereby lowering blood pressure. Probenecid is a uricosuric agent that blocks the renal tubular reabsorption of uric acid, increasing its urinary excretion and reducing hyperuricemia. This combination addresses both hypertension and elevated uric acid levels, which may co-occur in certain patient populations.","oneSentence":"Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while probenecid inhibits uric acid reabsorption in the kidney to reduce serum uric acid levels.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:58:04.748Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension with hyperuricemia or gout risk"}]},"trialDetails":[{"nctId":"NCT01907373","phase":"PHASE4","title":"Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Central South University","startDate":"2009-08","conditions":"Drug Interaction of Olmesartan in Healthy Chinese Volunteers","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"olmesartan medoxomil+probenecid","genericName":"olmesartan medoxomil+probenecid","companyName":"Central South University","companyId":"central-south-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while probenecid inhibits uric acid reabsorption in the kidney to reduce serum uric acid levels. Used for Hypertension with hyperuricemia or gout risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}